OTLK

Outlook Therapeutics, Inc.

Oncobiologics Inc is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing, manufacturing and commercializing complex biosimilar therapeutics in the disease areas of immunology and oncology.

Outlook Therapeutics, Inc. (OTLK) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (C+); its weakest is Growth (C).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.4
EV / EBITDA -1.9
Rev Growth YoY -99.4%
Gross Margin 0.0%
Price Return 3M -38.5%
Price Return 12M -67.7%
Catalyst Signal 0.00
Market Cap $100.5M
TTM Revenue -$1.2M
Price / Sales -86.4
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C (2.3) C (2.4) C+ (2.7) C+ (2.6) C+ (2.5)
2026-11-07 C+ (2.5) C (2.3) C (2.4) C (2.3) C+ (2.7) C (2.4)
2026-10-31 C+ (2.5) C (2.2) C (2.5) C (2.4) C+ (2.7) C (2.5)
2026-10-24 C+ (2.5) C (2.2) C (2.5) C (2.3) A+ (5.0) B- (2.9)
2026-10-17 C+ (2.5) C (2.2) C (2.4) C (2.2) A+ (5.0) B- (2.9)
Page 1 of 3